1. Introduction {#s0005}
===============

The prevalence of secondary failure to OHAs among T2DM patients taking oral agents particularly late into the disease, in different populations, ranges from 30% to 60% over 5 years after initiation of therapy ([@b0090], [@b0025]). Since the two OHA regimen has the potential to reduce the HbA1c levels on an average by only 1.2--2%, addition of a third agent either an oral agent or insulin is required in all patients in the future course of time with advancing T2DM ([@b0105]). Despite the triple OHA regimen is found to be statistically and clinically more effective in reducing HbA1c ([@b0070]), patients with triple OHA were less likely to complete the regimen due to an additive risk of adverse effects, dose adjustments may become complex or intolerable side effects ([@b0060], [@b0110]). On the other hand, insulin therapy has been shown to result in significant decreases in fasting plasma glucose (FPG) and HbA1c values ([@b0010]). However, large doses of insulin are often required to achieve near-normal blood glucose levels and are associated with weight gain and the risk of hypoglycemia ([@b0105]). Since both approaches have their respective advantages and disadvantages, this study compared the efficacy and safety in patients with two OHA failure randomly assigned to triple OHA therapy or insulin-based therapy.

2. Methods {#s0010}
==========

A qualitative prospective cohort study was conducted for a period of two years from June 2013 to June 2015 at Asir Diabetes Center, Asir Central Hospital in Abha, Saudi Arabia. The study was approved by the regional Research Ethical Committee. Both adult male and female insulin-naive T2DM patients currently on two OHA therapy, with a history of poor glycemic control and HbA1c \> 7% for the last one year or more were included in the study. Patients with a history of type 1 diabetes, elevated serum creatinine levels, lactic acidosis, gestational diabetes mellitus, and any other life-threatening complications were excluded from the study. Upon enrollment, study subjects were divided into two groups. In group I study subjects, a third OHA (gliptins or thiazolinediones) was added to their existing 2 OHA therapy (Sulfonylurea and Metformin), whereas group II included study subjects who were switched over to biphasic insulin and metformin from their existing 2 OHA therapy (Sulfonylurea and Metformin). Study subjects were followed regularly post-drug therapy intervention. HbA1c, Fasting plasma glucose (FPG), Postprandial Plasma Glucose (PPG), Blood Pressure (BP) and lipid profile data were collected from the study center at every three months based on the scheduled follow up visits of study subjects. Hypoglycemic episodes were obtained from patients' home blood glucose monitoring logs. Hypoglycemic episodes were defined as symptoms indicative of low blood glucose accompanied by a documented capillary blood glucose value of \<70 mg/dl. The primary objective of the study was to assess the change in HbA1c level at 1 year from the baseline. The secondary objectives were the changes in FPG, PPG, BP, weight, lipid profile and the number of hypoglycemic episodes. Statistical analyses were performed using SPSS software (IBM SPSS software, IBM Corp, V21 Armonk, NY, USA). Descriptive statistics were provided for all collected variables. Categorical data were summarized as frequency and percent­age, whereas quantitative data were summarized as mean and standard deviation. Baseline characteristics and change in the primary and secondary outcome parameters from baseline was done using ANOVA followed by Dunnet's test for post hoc analysis. p-value of \<0.05 was considered statistically significant.

3. Results {#s0015}
==========

A total of 129 patients were included in the study out of which 41.1% of patients (n = 53) received triple OHA regimen (group I) and 58.9% of patients (n = 76) received biphasic insulin and metformin regimen (group II). Both groups were well matched concerning gender ratio, age, body weight, BMI, HbA1c, and lipid profile with varying proportions of comorbidities \[[Table 1](#t0005){ref-type="table"}\]. Baseline HbA1c was 10.2 ± 1.7% for subjects in the triple oral therapy and 10.8 ± 1.7% in the biphasic insulin plus metformin group. The mean duration of diabetes was numerically longer in group II (11.63 ± 5.9 years) than in group I (8.23 ± 5.54 years). Before the transition, the most common combination used by the participants was sulfonylurea + metformin \[[Table 2](#t0010){ref-type="table"}\].Table 1Demographics and Baseline disposition of study subjects.CharacteristicsGroup I N (53)Group II N (76)Total for all Patients N (129)p-value**DEMOGRAPHY**Male32 (60.4)46 (60.5)78 (60.4)0.9887Age (Year)53.2 ± 8.754.1 ± 10.2553.3 ± 8.70.7373Total duration of diabetes (Mean years ± SD)8.23 ± 5.5411.63 ± 5.98.2 ± 5.50.02[\*](#tblfn1){ref-type="table-fn"}  **CLINICALBlood Pressure, mm Hg**Systolic[\*](#tblfn1){ref-type="table-fn"}120.1 ± 13.1123.8 ± 15.3123.5 ± 14.70.0342[\*](#tblfn1){ref-type="table-fn"}Diastolic76.2 ± 7.977.6 ± 9.277 ± 8.70.5913**Biochemical**HbA1C (%)10.2 ± 1.710.8 ± 1.710.6 ± 1.70.0573FPG (mg/dl)195.6 ± 62211.8 ± 63.6205.3 ± 63.30.0722PPG (mg/dl)236.5 ± 73.8283.4 ± 82.1263.9 ± 81.80.0004[\*](#tblfn1){ref-type="table-fn"}**Lipid Profile**HDL (mg/dl)39.2 ± 9.941.2 ± 10.840.4 ± 10.50.2715LDL (mg/dl)120 ± 36.1116.1 ± 35.6117.7 ± 35.70.5527TGL (mg/dl)155.5 ± 79.8169.4 ± 133.3163.4 ± 114.20.9637**Anthropometric**Body weight, Kg77.9 ± 12.777.1 ± 16.377.4 ± 14.80.5103BMI, kg/m^2^29.8 ± 4.330.3 ± 6.930.1 ± 60.6806[^1][^2]Table 2Drug therapy and coexisting conditions at the baseline.VariablesGroup I N (53)Group II N (76)Total for all Patients N (129)**Use of hypoglycemic agents**Metformin + Glibenclamide31 (58.5)43 (56.8)74 (57.4)Metformin + Glimipride16 (30.2)21(27.6)37 (28.7)Metformin + Gliclazide5 (9.4)10 (13.1)15 (11.6)Metformin + Repaclinide1 (1.9)01 (0.8)Metformin + Pioglitazone000Metformin + Roziglitazone1 (1.9)1 (1.3)2 (1.6)  **Coexisting conditions**Neuropathy4(5.88)16(21.1)20 (15.5)Retinopathy1(1.47)12(15.8)13 (10.1)Diabetic foot ulcer000Diabetic ketoacidosis05(6.6)5 (3.9)Impotence4(5.88)4(5.3)8 (6.2)Ischemic heart disease5(7.35)2(2.6)7 (5.4)Cerebrovascular Aneurism1(1.47)5(6.6)6 (4.7)Depression4(5.88)7(9.2)11 (8.5)

The maximal reduction in the mean HbA1c level occurred at the sixth month and then remained stable in group I, whereas the mean HbA1c level kept on decreasing till the end of the study in group II \[[Fig. 1](#f0005){ref-type="fig"}a, [Table 3](#t0015){ref-type="table"}\]. There was a significant reduction in HbA1c in biphasic insulin plus metformin group compared to the triple OHA group (8.18 ± 1.32 vs8.79 ± 1.81, p = 0.0238).Fig. 1Temporal assessment of primary and secondary outcomes during the study period. [Fig. 1](#f0005){ref-type="fig"}a shows mean levels of glycosylated hemoglobin in the four study groups. Figure-1b shows mean levels of fasting plasma glucose. Figure-1c shows mean levels of postprandial blood glucose. Figure-1d shows mean levels of body weight. I bar denote standard deviation.Table 3Post intervention impact on primary and secondary outcomes.VariablesGroup I N (53)Group II N (76)P value[†](#tblfn2){ref-type="table-fn"}PRIMARY OUTCOMEHbA1c(%)At I year8.79 ± 1.818.18 ± 1.320.0238[\*](#tblfn3){ref-type="table-fn"}Mean change from baseline−1.42−2.64  SECONDARY OUTCOMESFPGAt I year158 ± 44.5144.7 ± 43.80.0765Mean change from baseline−37.66−68.88PPGAt I year200.9 ± 82.4213.4 ± 67.30.4921Mean change from baseline−66.45−79.64SBPAt I year120.89 ± 13.9124.32 ± 15.90.0365Mean change from baseline−0.811.34DBPAt I year77.26 ± 9.177.16 ± 100.8559Mean change from baseline−0.84910.54HDLAt I year41.11 ± 11.738.46 ± 9.80.3364Mean change from baseline1.89−2.73LDLAt I year104.58 ± 27.4102.48 ± 32.90.3158Mean change from baseline−15.43−15.12TGLAt I year158.74 ± 81.9161.27 ± 10.50.7702Mean change from baseline3.26−13.71Body WtAt I year77.42 ± 13.282.73 ± 15.30.1793Mean change from baseline−0.464.48BMIAt I year29.59 ± 4.632.34 ± 6.60.0421[\*](#tblfn3){ref-type="table-fn"}Mean change from baseline−0.161.78% of patients achieved HbA1c target---no (%)≤ 7%11 (20.8)23 (30.3)Hypoglycemic incidences6(11.3)18 (23.7)[^3][^4][^5]

Percentage of subjects achieved HbA1c values ≤7% was 21 in group I and 30 in group II. There was no significant difference in the FPG reduction between the 2 groups (mean reduction from the baseline: 37.7 mg/dl vs 68.9 mg/dl, p = 0.07). There was a sharp reduction in FPG in both groups in the third month and continued to decrease in group II \[[Fig. 1](#f0005){ref-type="fig"}b\].

Reduction in mean PPG was −66.45 mg/dl in group I and 79.64 mg/dl in group II with no significant differences \[[Fig. 1](#f0005){ref-type="fig"}c\]. The change in body weight was statistically significant between the two groups with an increase in BMI by +0.16 kg/m2 in group I compared to +1.78 kg/m^2^ in group II (p = 0.042) \[[Fig. 1](#f0005){ref-type="fig"}d\]

Changes in lipid parameters are shown in [Fig. 2](#f0010){ref-type="fig"}. The baseline values of LDL, HDL, and triglycerides indicated no differences between the two treatment groups. Subjects in the triple oral therapy group showed a small increase in HDL and triglyceride levels, whereas, subjects in group II showed a small decrease in HDL.Fig. 2Mean changes in lipid profile from the baseline. Mean ± SD changes in HDL, LDL and triglyceride levels in the insulin plus metformin group as compared with thetripleOHA group.

No episodes of major hypoglycemia were recorded during the study period. The proportion of patients experiencing symptoms was not similar in the two groups. Of these study subjects, a total of 6 of 53 patients (11.3%) from group I and 18 of 76 (23.7%) from group II reported hypoglycaemic incidences.

4. Discussion {#s0020}
=============

T2DM is characterized by a progressive loss of β-cell function and glycemic control. Suboptimal glycemic control often results in microvascular and macrovascular complications ([@b0080]), which warrant the identification of effective and simple treatment regimens with high-level glycemic control and good patient compliance and convenience. The most recent ADA consensus statement ([@b0005]) encourages early use of insulin, whereas, commonly used agents such as gliptins and sodium-glucose cotransporter-2 (SGLT2) inhibitors are considered second tier. However, these guidelines faced criticisms such as insulin treatment is associated with hypoglycemia, weight gain, and low treatment satisfaction and compliance. In light of this dilemma, this study reports the glycemic control, cardiovascular risk factors, weight gain and rate of hypoglycemia.

Although most patients prefer OHAs over insulin, the addition of insulin to oral regimens is a well-established approach that is effective for many patients (American Diabetes Association; Standards of Medical Care in Diabetes 2019). Treatment modalities such as extended reliance on OHAs result in hyperglycemia for long periods, which contributes to microvascular complications and beta-cell destruction that in turn accelerates treatment failure. [@b0115] reported that insulin-based regimens are effective and safe as a short-term treatment option to gain rapid glycemic control. Therefore, the results of our study demonstrate that long-term continuation of insulin based regimens is effective, safe, and well accepted by patients as compared with a combination of triple OHA regimen.

Significant reduction in glycemic parameters such as the HbA1c, FPG, and PPG in both treatment groups was seen. However, as would be expected, the mean reductions in these parameters were found to be more prominent and statistically significant in group II rather than group I (mean reduction from the baseline: 2.64% vs 1.42%, p = 0.0238). These results were consistent with previous researches which reported the combination of insulin and metformin provided better glycemic control and treatment satisfaction ([@b0060], [@b0050]).

In the present study, Group II patients showed considerable and comparable improvement in FPG, PPG and other cardiovascular disease (CVD) risk factors such as systolic BP (SBP), diastolic BP (DBP) and lipid profile. This is in line with the results of the previous study comparing the efficacy and safety of premixed and basal-bolus insulin in the management of T2DM after the failure of two OHAs ([@b0100]). However, the patients in this group experienced higher incidences of hypoglycemic events. It confirms that biphasic insulin and metformin regimen is a better option in controlling glycemic parameters may be at the cost of increased adverse events (i.e., greater HbA1c reduction with increased hypoglycemia). This result is similar to the previous studies that reported that biphasic insulin and metformin regimen is more likely to cause hypoglycemia ([@b0030], [@b0085]).

Despite instituting intensified therapy, only one-fifth of subjects from group I and one third from group II were able to achieve an HbA1c value below 7%. Barriers in achieving target HbA1c maybe the severity and long duration of diabetes, certain classes of oral hypoglycemic agents are possibly less effective, fear of hypoglycemia by either subjects or physicians limiting further aggressive control, and noncompliance with recommended regimens ([@b0035], [@b0045]). Non-compliance is expected if polypharmacy is involved in glycemic control and other comorbid conditions of T2DM such as hypertension and dyslipidemia ([@b0075]).

An increase in body weight is one of the major side effects of insulin therapy. A noticeable increase in body weight was observed in those subjects treated with biphasic insulin and metformin (change in body weight from baseline = 4.48 kg). In group I subjects, body weight did not significantly change. In clinical practice, metformin is one of the most widely used agents in both obese and non-obese type 2 diabetes patients as a monotherapy or in combination with insulin, because of its ability to ameliorate insulin resistance and the potential effect of weight loss ([@b0120], [@b0065]). However, some studies have documented that metformin induces weight loss only when its daily dosage reached 2000--3000 mg ([@b0065], [@b0095]). In our study, the mean metformin dose was 1270 ± 387 mg/day, which was similar to a study conducted to evaluate the efficacy of biphasic insulin and metformin in T2DM patients ([@b0125]). More weight gain associated with premixed insulin use has been reported across trials ([@b0015], [@b0020], [@b0040]). However, dietary management and exercise programs need to be in place as part of the patient's treatment, especially when insulin is initiated.

Although many studies were conducted to find out the best therapeutic strategy after the failure of two OHA regimen in T2DM, the dilemma still exists. Previous studies have reported that an insulin and metformin regimen is effective and safe as a short-term treatment option to gain rapid glycemic control ([@b0055], [@b0060]). Data of this study shows that the long-term continuation of this regimen is effective in terms of glycemic control compared with a combination of three OHAs with some commonly known downsides such as weight gain and hypoglycemic events. These consequences can be overcome by tailoring the insulin regimen based on factors, including age, comorbidities, lifestyle, eating patterns, and psychological status of the patient.

This study demonstrated that treatment with biphasic insulin and metformin can be used to obtain significant glycemic control over tripe OHA treatment. The comparative assessment of these two approaches may further be substantiated with more evidence and can be used in clinical decision-making.

5. Limitations {#s0025}
==============

The results of this study should be understood based on the following limitations. The study was carried out for a limited period of one year. The study did not offer randomization of study subjects, as the patients were grouped at the physician's discretion. Moreover, hypoglycemic events were reported using patients' self-monitoring blood glucose logs only. In view of the above-mentioned limitations, further research is warranted to obtain more specific, significant and diverse outcomes.
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[^1]: Values are presented as n (%) or mean -- SD.

[^2]: P values \< 0.05 (statistically significant).

[^3]: Values are presented as n (%) or mean -- SD.

[^4]: The p values are for the comparisons between the groups at 1 year.

[^5]: P values \< 0.05 are statistically significant.
